Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/ijms21030777
Keywords
inherited retinal degeneration; retinitis pigmentosa; retinal disease; RNA editing; ADAR; CRISPR; gene therapy; gene editing; base editing; genome engineering
Funding
- NIHR Oxford Biomedical Research Centre
- Royal College of Surgeons of Edinburgh
- Rhodes Trust
- North Harbour Club Charitable Trust
- Amar-Franses & Foster-Jenkins Trust
Ask authors/readers for more resources
RNA editing aims to treat genetic disease through altering gene expression at the transcript level. Pairing site-directed RNA-targeting mechanisms with engineered deaminase enzymes allows for the programmable correction of G>A and T>C mutations in RNA. This offers a promising therapeutic approach for a range of genetic diseases. For inherited retinal degenerations caused by point mutations in large genes not amenable to single-adeno-associated viral (AAV) gene therapy such as USH2A and ABCA4, correcting RNA offers an alternative to gene replacement. Genome editing of RNA rather than DNA may offer an improved safety profile, due to the transient and potentially reversible nature of edits made to RNA. This review considers the current site-directing RNA editing systems, and the potential to translate these to the clinic for the treatment of inherited retinal degeneration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available